20231019-国金证券-建龙微纳-688357.SH-业绩逐步修复_新项目带来成长_4页_861kb

Performance Summary - 2023 Q3 Report Analysis

Key Financial Metrics

• Revenue for前三季度 (Jan-Sep 2023): 8 billion yuan, YoY +2,948%
• Net Profit: 136 billion yuan, YoY +56% (note: typo corrected from +056%)
• Q3 2023 Revenue: 30.2 billion yuan, YoY +413%
• Q3 2023 Net Profit: 610 million yuan, YoY +1381%, aligning with market expectations
• Significant YoY growth driven by robust industrial demand, particularly from the home medical oxygen and industrial gas sectors

Operating Analysis

• Revenue growth sustained amid higher operational expenses
• Strengthened partnerships and market penetration:
  • Expanded collaborations in home medical oxygen field
  • Gains in international markets: Supply agreements with leading global gas companies, including projects in Thailand, Congo, and other regions
  • Successful projects in energy and petrochemical sectors, e.g., RNG project supply with high-profile customers like Sinopec
• Enhanced product applications and competitive positioning through new projects
• Current capacities and in-progress expansions:
  • Formulated molecular sieve capacity: 47,000 tons
  • Raw material sieve capacity: 43,000 tons
  • Pending projects total investment: 26.3 billion yuan, including adsorption material park expansions and international facilities

Financial Forecasts and Ratings

• Revised 2023-2025 earnings projections:
  • Net profit forecast: 21.1 billion (2023), 30.1 billion (2024), 40.5 billion yuan (2025), reflecting upward adjustments
  • EPS and PE ratios recalculated, with PE values improving from high to moderate levels
• Maintained "Buy" rating based on strong revenue outlook and market recovery trends
• Valuation metrics show PE (2099X, 1471X, 1094X) and PB ratios indicating potential upside

Risk Assessment

• Potential delays in molecular sieve capacity expansion
• Uncertain pace of catalyst applications and market competition
• Risk of oversupplied scenarios and demand fluctuations across sectors

Overall Outlook

• The company is positioned to capitalize on global recovery in energy and medical industries, with expansions set to drive further growth and market share gains.